|
! Perkiraan prevalensi
|-
! rowspan="3" | [[TypeTipe I hyperlipoproteinemia|Type I]]
! a
! [[Hyperlipoproteinemia type Ia|a]]
| {{OMIM|238600||none}}
| Sindrom Buerger-Gruetz syndromeatau orhiperkilomikronemia familial hyperchylomicronemia
| DecreasedPenurunan [[lipoprotein lipase]] (LPL)
| rowspan="3" | [[ChylomicronsKilomikron]]
| rowspan="3" | [[AcutePankreatitis pancreatitis]]akut, [[lipemia retinalis]], eruptive skin [[xanthoma]]s kulit eruptif, [[hepatosplenomegalyhepatosplenomegali]]
| rowspan="3" | DietKontrol controldiet
| rowspan="3" | CreamyLapisan topatas layeryang lembut
| rowspan="3" | OneSatu indari 1,.000,.000<ref>{{cite web | title = Hyperlipoproteinemia, Type I | date = 6 March 2007 | url = http://www.cags.org.ae/FMPro?-DB=ctga.fp5&-Format=ctga%2Fctga_detail.html&-RecID=34563&-Find | archive-url = https://web.archive.org/web/20120327213629/http://www.cags.org.ae/FMPro?-DB=ctga.fp5&-Format=ctga%2Fctga_detail.html&-RecID=34563&-Find | archive-date=27 March 2012 | work = Centre for Arab Genomic Studies | quote = About 1:1,000,000 people are affected with Hyperlipoproteinemia type I worldwide with a higher prevalence in some regions of Canada. }}</ref>
|-
! b
! [[hyperlipoproteinemia type Ib|b]]
| {{OMIM|207750||none}}
| FamilialDefisiensi apoprotein CIIfamilial deficiencyCII
| ApoC2 yang diubah
| Altered [[apolipoprotein C2|ApoC2]]
|-
! c
! [[Hyperlipoproteinemia type Ic|c]]
| {{OMIM|118830||none}}
|
| Penghambat lipoprotein lipase dalam darah
| [[Lipoprotein lipase|LPL]] inhibitor in blood
|-
! rowspan="2" | TypeTipe II
! a
| {{OMIM|143890||none}}
| [[Hiperkolesterolemia familia]]
| [[Familial hypercholesterolemia]]
| Defisiensi reseptor LDL
| [[LDL receptor]] deficiency
| [[Lipoprotein densitas rendah|LDL]]
| [[Xanthelasma]], [[arcusarkus senilis]], tendonxanthoma xanthomastendon
| [[BilePengikat acidasam sequestrant]]sempedu, [[statin]]s, [[niacinniasin (substance)|niacin]]
| ClearJernih
| OneSatu indari 500 foruntuk heterozygotesheterozigot
|-
! b
| {{OMIM|144250||none}}
| Hiperlipidemia gabungan familial
| Familial combined hyperlipidemia
| Penurunan reseptor LDL dan peningkatan ApoB
| Decreased [[LDL receptor]] and increased [[apolipoprotein B|ApoB]]
| [[LDL]] anddan [[VLDL]]
|
| StatinsStatin, niacinniasin, [[fibratefibrat]]
| TurbidKeruh
| Onesatu indari 100
|-
! colspan="2" | TypeTipe III
| {{OMIM|107741||none}}
| [[Disbetalipoproteinemia familia]]
| [[Familial dysbetalipoproteinemia]]
| DefectCacat indalam [[apolipoproteinsintesis E|Apo E 2]] synthesis
| IDL
| [[Intermediate density lipoprotein|IDL]]
| Xantoma tubereruptif dan xantoma palmaris
| Tuberoeruptive xanthomas and palmar xanthomas
| FibrateFibrat, statinsstatin
| TurbidKeruh
| Onesatu indari 10,.000<ref name="fung2011">{{cite journal | vauthors = Fung M, Hill J, Cook D, Frohlich J | title = Case series of type III hyperlipoproteinemia in children | journal = BMJ Case Reports | volume = 2011 | pages = bcr0220113895 | date = June 2011 | pmid = 22691586 | pmc = 3116222 | doi = 10.1136/bcr.02.2011.3895 }}</ref>
|-
! colspan="2" | TypeTipe IV
| {{OMIM|144600||none}}
| [[Hipertrigliseridemia familia]]
| [[Familial hypertriglyceridemia]]
| Peningkatan produksi VLDL dan penurunan eliminasi
| Increased VLDL production and decreased elimination
| VLDL
|Dapat menyebabkan [[pankreatitis]] pada kadar trigliserida tinggi
|Can cause [[pancreatitis]] at high triglyceride levels
| FibrateFibrat, niacinniasin, statinsstatin
| TurbidKeruh
| Onesatu indari 100
|-
! colspan="2" | [[#typeTipe V|Type V]]
| {{OMIM|144650||none}}
|
| IncreasedPeningkatan VLDLproduksi productionVLDL anddan decreasedpenurunan [[Lipoproteinlipoprotein lipase|LPL]]
| VLDL anddan chylomicronskilomikron
|
| NiacinNiasin, fibratefibrat
| Lapisan atas yang lembut dan bagian bawah keruh
| Creamy top layer and turbid bottom
|
|}
| 